![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/genfleet-receives-ind-approval-from-chinas-nmpa-for-gfh375-an-oral-kras-g12d-onoff-inhibitor-in-a-phase-iii-clinical-trial-treating-advanced-solid-tumor-patients-with-kras-g12d-mutation-302176685.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-efficacy--safety-result-from-phase-ii-trial-for-first-line-nsclc-treatment-in-krocus-study-fulzerasib-kras-g12c-inhibitor-in-combination-with-cetuximab-in-a-late-breaking-abstract-at-the-oral-p-302161182.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-fdas-clinical-trial-approval-for-gfh925-kras-g12c-inhibitor-monotherapy-in-phase-iii-registrational-study-treating-metastatic-colorectal-cancer-302121725.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-potent-anti-tumor-efficacy-of-gfh375-an-oral-kras-g12d-onoff-inhibitor-and-its-potential-in-combination-therapy-with-rafmek-clamp-at-2024-aacr-annual-meeting-302111376.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-broad-spectrum-activity-of-gfh547-an-oral-panras-on-inhibitor-and-its-potential-to-overcome-resistance-against-siip-based-kras-inhibitors-in-late-breaking-research-abstract-of-2024-aacr-annual-m-302111456.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-gfh009-granted-with-fda-fast-track-orphan-drug-designations-for-treating-rr-peripheral-t-cell-lymphomas-and-acute-myeloid-leukemia-302032022.html
https://www.prnewswire.com/news-releases/chinas-first-nda-for-a-kras-g12c-inhibitor-nmpa-accepts-new-drug-application-for-gfh925-and-grants-gfh925-with-priority-review-designation-301996973.html
https://www.prnewswire.com/news-releases/genfleet-starts-phase-ibii-trial-of-gfh009-highly-selective-cdk9-inhibitor-treating-patients-with-relapsedrefractory-peripheral-t-cell-lymphomas-ptcl-301952001.html